Investor Presentaiton

Investor presentation First three months of 2017 Slide 40 Maintaining global insulin leadership by sustaining modern and new generation insulin market share Novo Nordisk global volume market share across insulin classes tMU 500 Human insulin¹ tMU MI and NGI³ class volume tMU Novo Nordisk class MS (%) Total insulin 100% 500 100% 500 100% Market value²: 400 DKK 25 billion 80% 400 Market value²: DKK 220 billion 80% 400 Market value²: DKK 244 billion 80% 300 60% 300 60% 300 60% 200 100 40% 200 40% 200 20% 100 + 20% 100 0 Feb 2012 0% 0 Feb Feb 2017 2012 0% Feb 2017 40% 20% 0% Feb Feb 2012 2017 1 Includes animal insulin. 2 Annual value of total insulin class. 3 MI: Modern insulin. NGI: New generation insulin Note: Data is sensitive to changes in IMS data collection and reporting methodology Source: IMS, Monthly MAT February, 2017 value and volume figures changing diabetes® novo nordisk

View entire presentation